Nuvation Bio Inc (NUVB) concluded trading on Thursday at a closing price of $1.75, with 4.56 million shares of worth about $7.97 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -21.52% during that period and on April 10, 2025 the price saw a loss of about -2.23%. Currently the company’s common shares owned by public are about 336.84M shares, out of which, 226.72M shares are available for trading.
Stock saw a price change of 5.42% in past 5 days and over the past one month there was a price change of -21.88%. Year-to-date (YTD), NUVB shares are showing a performance of -34.21% which decreased to -45.82% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.54 but also hit the highest price of $3.97 during that period. The average intraday trading volume for Nuvation Bio Inc shares is 2.66 million. The stock is currently trading -5.69% below its 20-day simple moving average (SMA20), while that difference is down -14.45% for SMA50 and it goes to -33.00% lower than SMA200.
Nuvation Bio Inc (NYSE: NUVB) currently have 336.84M outstanding shares and institutions hold larger chunk of about 45.74% of that.
The stock has a current market capitalization of $592.69M and its 3Y-monthly beta is at 1.44. It has posted earnings per share of -$2.25 in the same period. It has Quick Ratio of 9.04 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NUVB, volatility over the week remained 13.52% while standing at 8.10% over the month.
Stock’s fiscal year EPS is expected to rise by 73.12% while it is estimated to decrease by -12.85% in next year. EPS is likely to grow at an annualized rate of 37.20% for next 5-years, compared to annual growth of -49.14% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on March 27, 2024 offering a Buy rating for the stock and assigned a target price range of between $1.40 and $10 to it. Coverage by BTIG Research stated Nuvation Bio Inc (NUVB) stock as a Buy in their note to investors on March 26, 2024, suggesting a price target of $5 for the stock. Stock get a Market perform rating from BMO Capital Markets on August 02, 2022.
